Accrol Group Holdings plc (the “Company” or “Accrol”)
Audited full year results for the year ended 30 April 2016
Accrol Group Holdings plc, the AIM listed leading independent tissue converter, today announces its audited results for the financial year ended 30 April 2016.
Financial Highlights(1) — Revenue increased 17% to GBP118m (2015: GBP101m)
— Adjusted Gross Margin increased 2.1% to 28.1% (2015: 26.0%)
— Adjusted EBITDA of GBP15.0m, up 22% (2015: GBP12.3m)
— Continued strong cash generation year-on-year
— Net debt reduced by GBP1.1m
— Successful IPO on London Stock Exchange's AIM market on 10 June 2016
Operational Highlights(1)
— 35% market share of the Discount sector (Discounters accounting for 69% of revenues, up 6% on 2015) after contract wins during the year
— 15% increase in sales to Multiples
— Focus on Private Label products which are taking market share from Brands
— Continued investment in machinery with GBP3.2m invested in two high-speed converting lines
— Capacity increased to 118,000 tonnes with a further 25,000 tonnes to be added
— UK exclusivity secured for a new luxury tissue, NTT (New Textured Tissue)
…